Appendix 2.
Peer Reviewer | Representation | Consultant | Speaker | Ownership/Partnership/Principal | Research | Institutional, Organizational, or Other Financial Benefit | Expert Witness |
---|---|---|---|---|---|---|---|
Dr. James C. Carr | Official Reviewer—North American Society for Cardiovascular Imaging | None | None | None | None | None | None |
Dr. Michael G. Del Core | Official Reviewer—ACCF Board of Governors | None | None | None | None | None | None |
Dr. Andre Duerinckx | Official Reviewer—American College of Radiology | None | None | None | • Philips Medical Systems • Schering-Plough |
None | None |
Dr. Mark J. Eisenberg | Official Reviewer—ACCF Task Force on Clinical Expert Consensus Documents | None | None | None | None | None | None |
Dr. Victor A. Ferrari | Official Reviewer—Society for Cardiovascular Magnetic Resonance Imaging | None | None | None | None | None | None |
Dr. Gautham Reddy | Official Reviewer—American College of Radiology | None | None | None | None | None | None |
Dr. Orlando Simonetti | Official Reviewer—North American Society for Cardiovascular Imaging | None | None | • Siemens Healthcare | None | None | None |
Dr. James E. Udelson | Official Reviewer—ACCF Board of Trustees; American Heart Association | None | None | None | None | None | None |
Dr. Sanjay Kaul | Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents | None | None | None | None | None | None |
Dr. Debabrata Mukherjee | Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents | None | None | None | None | None | None |
Dr. Robert S. Rosenson | Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents | • Abbott • Anthera • AstraZeneca* • Daiichi Sankyo • LipoScience* • Roche |
None | • LipoScience* | None | • Grain Board | None |
Dr. Jonathan W. Weinsaft | Content Reviewer—*Individual | None | None | None | • Lantheus Medical Imaging | None | None |
This table represents the relevant relationships with industry and other entities that were disclosed by reviewers at the time of peer review. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Participation in the peer review process does not imply endorsement of this document.
Significant (greater than $10 000) relationship.